Waters Corporation (WATERS CORP) - 10-Q Summary
Business Context and Reporting Period
Company: Waters Corporation, a manufacturer of analytical instruments including high performance liquid chromatography (HPLC), mass spectrometry (MS), and thermal analysis systems. The company also operates in the laboratory informatics market following recent acquisitions.
Reporting Period: Quarterly report (Form 10-Q) for the three and nine months ended October 2, 2004.
Share Count: 120,839,223 shares of common stock outstanding as of November 3, 2004.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Oct 2, 2004 | 9 Months Ended Oct 2, 2004 |
|---|---|---|
| Total Net Sales | $264,808 | $780,382 |
| Gross Profit | $153,799 | $455,719 |
| Gross Margin | 58.1% | 58.4% |
| Operating Income | $63,761 | $193,472 |
| Net Income | $51,940 | $152,536 |
| Diluted EPS | $0.42 | $1.24 |
| Cash from Operations (9mo) | $190,965 | |
| Cash and Equivalents (Oct 2, 2004) | $471,171 | |
| Total Debt (Oct 2, 2004) | $392,697 (Short-term: $282.7M; Long-term: $110.0M) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15% for the quarter and 14% for the nine-month period compared to 2003. Excluding currency effects, organic growth was 11% (quarter) and 9% (nine months).
- Profitability: Operating income rose 35% for both the quarter and nine-month period. Net income increased 43% for the quarter and 36% for the nine-month period.
- Product Mix: Service sales grew 30% (quarter) and 27% (nine months), outpacing product sales growth (10% for both periods). HPLC sales grew 10% (quarter) driven by the new ACQUITY UPLC system. Mass Spectrometry sales grew 5% (quarter) but declined 5% (nine months) due to a transition between product lines.
- Acquisitions: The acquisition of NuGenesis Technologies (Feb 2004) and Creon Lab Control AG (July 2003) contributed to sales growth in the Laboratory Informatics segment.
- Debt Levels: Total borrowings increased significantly to fund share repurchases. Borrowings under credit facilities rose from $100.0 million (Dec 2003) to $205.0 million (Oct 2004) on the revolving line, with the $125.0 million term loan fully drawn.
Guidance, Outlook, and Risks
- Share Repurchases: The company completed a $400 million buyback program in June 2004. On October 25, 2004, the Board authorized a new $500 million repurchase program over two years. As of November 4, 2004, $11.6 million had been utilized under the new program.
- Product Launches: Management expects to begin shipping the Q-Tof Premier mass spectrometer and the E-Lab Notebook software in the fourth quarter of 2004.
- Litigation:
- Perkin-Elmer: Litigation concluded with a $17.4 million payment received by Waters (recorded as a benefit in Q2 2004).
- Applera: Patent litigation settled in March 2004 with a one-time payment of $18.1 million by Waters.
- Hewlett-Packard: Ongoing patent infringement suits in England and France. Waters recorded a $7.8 million provision in Q1 2004. A trial on damages was rescheduled to November 2004.
- Restructuring: A 2004 restructuring plan involving 70 terminations was completed with a $2.1 million charge. The company also reversed $2.2 million in accruals from a 2002 restructuring plan due to changes in facility closure plans.
- Tax Rate: The effective tax rate for the nine months ended Oct 2, 2004, was 21.8%, down from 23.6% in the prior year, largely due to higher profitability in international jurisdictions with lower tax rates.
Investor Verification Checklist
- Debt Utilization: Verify the impact of the $392.7 million in total debt on future interest expenses and liquidity, given the aggressive share repurchase strategy.
- Litigation Exposure: Monitor the outcome of the Hewlett-Packard patent trials scheduled for late 2004, as additional provisions may be required.
- Product Transition: Assess the success of the Q-Tof Premier launch in Q4 2004 to ensure it offsets the decline in legacy Q-Tof sales.
- Service Growth: Confirm the sustainability of the 30% growth in service sales, which is a key driver of margin stability.
- Acquisition Integration: Review the integration progress of NuGenesis and Creon to ensure projected synergies in the Laboratory Informatics segment are realized.